Dr. David W. Shen is a well-recognized expert in the antibody and therapeutic protein field with a proven record of advancing pipelines from discovery to proof-of-concept in clinical stage. As an executive leading research and process development teams in top biotech and big pharma companies, he brings strong interpersonal skills, extensive experience in building collaborative relationships both inside and outside the organization, and success in working in a matrix environment. Innovatively blending the scientific and industrial vision, he brings a proven history of discovering new technologies (20 patents or applications and more than 20 peer reviewed papers) with strong industrial application potential.Specialties: Therapeutic antibody and protein drug discovery, engineering, and profiling. Experienced in phage display, hybridoma, protein/mAb engineering, humanization, optimization, and characterization. Developed a novel mammalian display of antibody IgGs. Leads process development and CMC group including immunoassay and potency assay.
-
Founder And CeoPropeller BioCalifornia, United States
-
Founder And CeoProteologix Inc Jul 2021 - PresentUnited StatesProteologix is an innovative biotech company focused on immunology and inflammation diseases (I&I). We discover and develop highly differentiated multi-specific, multi-functional antibody drugs to break efficacy ceiling and, at the same time, to extend the half-life of the molecules for less frequent dosing. We are a clinical ready company with lead programs ready for clinical trials in atopic dermatitis, asthma, and other I&I diseases. Proteologix was recently acquired by J&J for $850M plus milestone in less than three years after initiation of the company in 2021.
-
Board Member And Chairman Of Scientific Advisory BoardElpiscience Biopharmaceuticals, Lilly Asia Venture Backed Comapny Oct 2017 - Apr 2022Shanghai/San Francisco
-
Senior Vice President, Head Of Biologics Research, Bioanalyticals, And CmcNgm Biopharmaceuticals Oct 2013 - Jul 2021South San FranciscoDavid is a member of Executive Committee at NGM that sets the strategy for first-in-class, innovative biologics and the pipeline portfolio. He is head of biologic research (antibody and protein sciences), bioanalytical assays (PK and immunogenicity assays), process development,and CMC up to commercialization. -
Global Vp, Global Head Of Biologics DevelopmentTeva Pharmaceuticals Nov 2010 - Sep 2013Vice President, Global Head of Biologics Development in the Branded Products R&D at TEVA Pharmaceuticals, David is a critical member of the leadership team that sets the strategy for BioSimilars, BioBetters and innovative biologics including their pipeline portfolio. In this capacity, he oversees research, process development, bioassay Center of Excellence (including but not limited to functional assays, PK assays, potency assays, immunogenicity assays), and CMC up to phase III clinical materials. -
Board Member, Managing Director, Head Of Joint VentureTeva-Lonza Biopharmarceuticals Nov 2010 - Sep 2013
-
Executive Director, Head Of Biologics Research And Glycofi, Merck Research LaboratoryMerck & Co. Usa Mar 2008 - Nov 2010Prior to TEVA, David worked with Merck serving as Executive Director of Biologics Research and GlycoFi overseeing two research sites with more than 100 staff supporting all 7 therapeutic areas across all research labs. His department worked on innovative therapeutic antibody, protein based drug and follow-on biologics (biosimilars and biobetters). David led his leadership team to develop a clear strategy to position Merck Biologics in the right direction for growth through balancing their portfolio with both innovative and follow-on biologics and championing for corporate partnerships to further balance the Biologics Portfolio.
-
Director Of Protein Sciences, Head Of Amgen Sf SiteAmgen 1995 - 2008His professional career started at Amgen where David held positions of increasing responsibilities and most recently became Director and Head of Protein Science Department at the San Francisco research facility and led a group working on therapeutic antibody, protein based drug discovery for oncology, inflammation, metabolic disorders, and neurosciences. Before moving to San Francisco, he was a group leader for antibody engineering, where they played key roles for more than 8 antibodies currently in early and late stage clinical trials. His group developed a novel Mammalian Antibody Display technology for antibody discovery/selection, which for the first time allows functional display of full length IgG on mammalian cell surface. -
Postdoctor Associate, MitWhitehead Institute 1991 - 1995
David W. Shen Education Details
-
Biochemistry -
Biochemistry
Frequently Asked Questions about David W. Shen
What company does David W. Shen work for?
David W. Shen works for Propeller Bio
What is David W. Shen's role at the current company?
David W. Shen's current role is Founder and CEO.
What schools did David W. Shen attend?
David W. Shen attended University Of Toronto, East China University Of Science And Technology.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial